Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | KDM5A | P29375 | 7/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 7/20 | 0.39 |
| ▸ | KDM5B | Q9UGL1 | 7/20 | 0.39 |
| ▸ | KDM2B | Q8NHM5 | 3/20 | 0.39 |
| ▸ | PPARA | Q07869 | 3/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | KDM4A | O75164 | 2/20 | 0.38 |
| ▸ | ANO1 | Q5XXA6 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.37 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.36 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16921596 | 0.93 | BRD4 (0.43) | BRD4KDM5AKDM4CKDM5BKDM2B | |
| SCHEMBL756684 | 0.92 | BRD4 (0.42) | BRD4KDM5AKDM4CKDM5BKDM2B | |
| SCHEMBL753747 | 0.92 | KDM5A (0.42) | BRD4KDM5AKDM5BLMNAABCB1 | |
| SCHEMBL755553 | 0.91 | BRD4 (0.41) | BRD4KDM5AKDM4CKDM5BPPARA | |
| SCHEMBL3432852 | 0.89 | BRD4 (0.40) | BRD4KDM5AKDM4CKDM5BKDM2B | |
| SCHEMBL754597 | 0.88 | BRD4 (0.39) | BRD4KDM5AKDM5BANO1ABCB1 | |
| SCHEMBL752441 | 0.88 | BRD4 (0.40) | BRD4KDM5AKDM4CKDM5BKDM2B | |
| SCHEMBL754396 | 0.86 | BRD4 (0.41) | BRD4LMNAHTTABCB1 | |
| SCHEMBL18531618 | 0.86 | BRD4 (0.39) | BRD4KDM5AKDM4CKDM5BKDM2B | |
| SCHEMBL752863 | 0.84 | BRD4 (0.44) | BRD4KDM5AKDM4CKDM5BKDM2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2266958-B1 | Antiviral agent | SHIONOGI & CO (JP) | 2017-03-15 | — | — | EP | disclosed |
| US-20170066754-A1 | ANTIVIRAL AGENT | SHIONOGI & CO., LTD. (JP) | 2017-03-09 | — | — | US | disclosed |
| US-9572813-B2 | Antiviral agent | SHIONOGI & CO., LTD. (JP) | 2017-02-21 | — | — | US | disclosed |
| EP-3042894-A1 | ANTIVIRAL AGENT | SHIONOGI & CO., LTD. (JP) | 2016-07-13 | — | — | EP | disclosed |
| US-20150202208-A1 | ANTIVIRAL AGENT | SHIONOGI & CO., LTD. (JP) | 2015-07-23 | — | — | US | disclosed |
| EP-2181985-B1 | Antiviral Agent | SHIONOGI & CO (JP) | 2011-10-26 | — | — | EP | disclosed |
| EP-2266958-A1 | Antiviral agent | SHIONOGI & CO., LTD. (JP) | 2010-12-29 | — | — | EP | disclosed |
| EP-2181985-A1 | Antiviral Agent | SHIONOGI & CO., LTD. (JP) | 2010-05-05 | — | — | EP | disclosed |
| US-20040229909-A1 | Antiviral agent | SHIONOGI & CO., LTD. (JP) | 2004-11-18 | — | — | US | disclosed |
| EP-1422218-A1 | ANTIVIRAL AGENT | SHIONOGI & CO., LTD. (JP) | 2004-05-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229909-A1 | Antiviral agent | ZC3HAV1, ZC3HAV1L, DUT | BRD4 586/4885KDM5A 415/4885KDM4C 334/4885 |
| US-20150202208-A1 | ANTIVIRAL AGENT | ZC3HAV1, ZC3HAV1L, CCNI | BRD4 427/4885KDM5A 350/4885KDM4C 353/4885 |
| US-20170066754-A1 | ANTIVIRAL AGENT | ZC3HAV1, ZC3HAV1L, CCNI | BRD4 427/4885KDM5A 350/4885KDM4C 353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.